Joshua Roark, MD
Interventional Cardiology · Portland, ORNPI 1619389368
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (58.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Medtronic at 32.9% of the total. Reporting peaked in 2023 at $5,438 and has fallen 90.6% since, to $513 in 2025.
Across 141 payments — averaging $111.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Abiomed$4K
- Abbott$3K
- CSL Behring$2K
- Angiodynamics, Inc.$261
- Shockwave Medical, Inc$180
- plus $591 from 8 others
What the payments were for
- Travel & lodging$9,22659%
- Food & beverage$6,33240%
- Education$2111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 39 | $5,192 |
| Abiomed | 44 | $4,482 |
| Abbott | 22 | $2,672 |
| CSL Behring | 11 | $2,391 |
| Angiodynamics, Inc. | 2 | $261 |
| Shockwave Medical, Inc | 4 | $180 |
| Philips North America LLC | 6 | $171 |
| Pfizer | 4 | $159 |
| Stryker | 3 | $148 |
| Penumbra, Inc. | 2 | $47 |
| Edwards Lifesciences | 1 | $25 |
| Boston Scientific | 1 | $18 |
| Boehringer Ingelheim | 1 | $11 |
| Cardiovascular Systems Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$3,486
- SUPERA$1,736
- RESOLUTE ONYX$1,316
- AlphaVac$241
- Ensite Cardiac Mapping System$211
- JETI$174
- ELIQUIS$135
- Dragonfly OCT$114
- FlowTriever$111
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$108
How this compares
$15,769 in reported general payments places this provider in the 70th percentile of 68 interventional cardiology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 101 | $140,588 |
| EntrestoSacubitril/Valsartan | 40 | $50,791 |
| JardianceEmpagliflozin | 18 | $21,214 |
| Repatha SureclickEvolocumab | 13 | $8,558 |
| Ranolazine ErRanolazine | 44 | $4,476 |
| Metoprolol Succinate | 253 | $3,551 |
| Atorvastatin Calcium | 141 | $1,626 |
| ClopidogrelClopidogrel Bisulfate | 117 | $1,450 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 88 | $1,350 |
| Amiodarone Hcl | 36 | $1,098 |
| Losartan Potassium | 104 | $1,054 |
| Rosuvastatin Calcium | 64 | $705 |
| Carvedilol | 76 | $616 |
| Ezetimibe | 21 | $541 |
| Amlodipine Besylate | 66 | $424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $159 | $140,588101 claims |
| Boehringer IngelheimJardiance | $11 | $21,21418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 68 interventional cardiology providers in Oregon.
Other interventional cardiology in Portland
- Jason WollmuthPortland$749K
- Ethan KorngoldPortland$407K
- Amish DesaiPortland$186K
- Harsh GolwalaPortland$105K
- Brandon JonesPortland$101K
- Kathryn DawsonPortland$57K
- Logan VincentPortland$42K
- Amged AbdelazizPortland$38K
- Richard SohnPortland$38K
- Daniel FeldmanPortland$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.